Pyridam Farma Tbk
PT Pyridam Farma Tbk engages in the development, production, and trading of pharmaceuticals primarily in Indonesia. The company operates through Pharmaceutical Products, Esthetic, and Toll Manufacturing Services; and Medical Equipments segments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extra… Read more
Pyridam Farma Tbk (PYFA) - Net Assets
Latest net assets as of September 2025: Rp732.89 Billion IDR
Based on the latest financial reports, Pyridam Farma Tbk (PYFA) has net assets worth Rp732.89 Billion IDR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp6.92 Trillion) and total liabilities (Rp6.19 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp732.89 Billion |
| % of Total Assets | 10.59% |
| Annual Growth Rate | 13.16% |
| 5-Year Change | 559.48% |
| 10-Year Change | 927.0% |
| Growth Volatility | 49.62 |
Pyridam Farma Tbk - Net Assets Trend (2001–2024)
This chart illustrates how Pyridam Farma Tbk's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pyridam Farma Tbk (2001–2024)
The table below shows the annual net assets of Pyridam Farma Tbk from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp1.04 Trillion | +191.14% |
| 2023-12-31 | Rp357.06 Billion | -19.28% |
| 2022-12-31 | Rp442.36 Billion | +164.73% |
| 2021-12-31 | Rp167.10 Billion | +6.01% |
| 2020-12-31 | Rp157.63 Billion | +26.38% |
| 2019-12-31 | Rp124.73 Billion | +4.88% |
| 2018-12-31 | Rp118.93 Billion | +9.25% |
| 2017-12-31 | Rp108.86 Billion | +3.17% |
| 2016-12-31 | Rp105.51 Billion | +4.23% |
| 2015-12-31 | Rp101.22 Billion | +4.25% |
| 2014-12-31 | Rp97.10 Billion | +3.40% |
| 2013-12-31 | Rp93.90 Billion | +7.06% |
| 2012-12-31 | Rp87.71 Billion | +6.44% |
| 2011-12-31 | Rp82.40 Billion | +6.70% |
| 2010-12-31 | Rp77.23 Billion | +5.75% |
| 2009-12-31 | Rp73.03 Billion | +5.45% |
| 2008-12-31 | Rp69.25 Billion | +3.45% |
| 2007-12-31 | Rp66.94 Billion | +2.67% |
| 2006-12-31 | Rp65.20 Billion | +2.72% |
| 2005-12-31 | Rp63.47 Billion | +2.14% |
| 2004-12-31 | Rp62.14 Billion | +2.36% |
| 2003-12-31 | Rp60.71 Billion | +1.03% |
| 2002-12-31 | Rp60.09 Billion | -0.71% |
| 2001-12-31 | Rp60.52 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pyridam Farma Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 572.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rp1.12 Trillion | 108.09% |
| Other Comprehensive Income | Rp-41.39 Billion | -3.98% |
| Other Components | Rp2.07 Billion | 0.20% |
| Total Equity | Rp1.04 Trillion | 100.00% |
Pyridam Farma Tbk Competitors by Market Cap
The table below lists competitors of Pyridam Farma Tbk ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Baolijia Chemical Co. Ltd.
SHE:301037
|
$76.04 Million |
|
Monument Mining Limited
PINK:MMTMF
|
$76.06 Million |
|
Siyaram Silk Mills Limited
NSE:SIYSIL
|
$76.10 Million |
|
Taj GVK Hotels & Resorts Limited
NSE:TAJGVK
|
$76.11 Million |
|
Interactive Digital Technologies
TWO:6486
|
$76.03 Million |
|
Kernel Holding S.A
PINK:KARNF
|
$76.01 Million |
|
Prime Office A/S
CO:PRIMOF
|
$76.00 Million |
|
Fast Ejendom
CO:FED
|
$76.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pyridam Farma Tbk's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 356,833,920,095 to 1,039,539,307,000, a change of 682,705,386,905 (191.3%).
- Net loss of 330,246,642,000 reduced equity.
- Dividend payments of 31,630,163,000 reduced retained earnings.
- Share repurchases of 1,070,161,504,800 reduced equity.
- New share issuances of 1,070,161,504,800 increased equity.
- Other comprehensive income decreased equity by 57,209,511,628.
- Other factors increased equity by 1,101,791,703,533.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp-330.25 Billion | -31.77% |
| Dividends Paid | Rp31.63 Billion | -3.04% |
| Share Repurchases | Rp1.07 Trillion | -102.95% |
| Share Issuances | Rp1.07 Trillion | +102.95% |
| Other Comprehensive Income | Rp-57.21 Billion | -5.5% |
| Other Changes | Rp1.10 Trillion | +105.99% |
| Total Change | Rp- | 191.32% |
Book Value vs Market Value Analysis
This analysis compares Pyridam Farma Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.57x to 2.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | Rp23.72 | Rp322.00 | x |
| 2006-12-31 | Rp24.37 | Rp322.00 | x |
| 2007-12-31 | Rp25.02 | Rp322.00 | x |
| 2008-12-31 | Rp25.89 | Rp322.00 | x |
| 2009-12-31 | Rp27.30 | Rp322.00 | x |
| 2010-12-31 | Rp28.86 | Rp322.00 | x |
| 2011-12-31 | Rp30.80 | Rp322.00 | x |
| 2012-12-31 | Rp32.78 | Rp322.00 | x |
| 2013-12-31 | Rp35.10 | Rp322.00 | x |
| 2014-12-31 | Rp36.29 | Rp322.00 | x |
| 2015-12-31 | Rp37.83 | Rp322.00 | x |
| 2016-12-31 | Rp39.44 | Rp322.00 | x |
| 2017-12-31 | Rp203.44 | Rp322.00 | x |
| 2018-12-31 | Rp222.26 | Rp322.00 | x |
| 2019-12-31 | Rp233.10 | Rp322.00 | x |
| 2020-12-31 | Rp63.25 | Rp322.00 | x |
| 2021-12-31 | Rp312.29 | Rp322.00 | x |
| 2022-12-31 | Rp826.28 | Rp322.00 | x |
| 2023-12-31 | Rp143.18 | Rp322.00 | x |
| 2024-12-31 | Rp122.47 | Rp322.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pyridam Farma Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.19%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 5.59x
- Recent ROE (-31.77%) is below the historical average (4.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 7.76% | 16.06% | 0.38x | 1.27x | Rp-1.36 Billion |
| 2002 | 0.73% | 1.77% | 0.35x | 1.16x | Rp-5.57 Billion |
| 2003 | 1.02% | 2.27% | 0.40x | 1.12x | Rp-5.45 Billion |
| 2004 | 2.30% | 4.21% | 0.48x | 1.13x | Rp-4.78 Billion |
| 2005 | 2.09% | 3.35% | 0.52x | 1.21x | Rp-5.02 Billion |
| 2006 | 2.65% | 2.82% | 0.74x | 1.27x | Rp-4.79 Billion |
| 2007 | 2.60% | 2.01% | 0.91x | 1.42x | Rp-4.95 Billion |
| 2008 | 3.33% | 1.93% | 1.21x | 1.42x | Rp-4.62 Billion |
| 2009 | 5.17% | 2.86% | 1.32x | 1.37x | Rp-3.53 Billion |
| 2010 | 5.44% | 2.98% | 1.40x | 1.30x | Rp-3.52 Billion |
| 2011 | 6.28% | 3.42% | 1.28x | 1.43x | Rp-3.07 Billion |
| 2012 | 6.05% | 3.00% | 1.30x | 1.55x | Rp-3.46 Billion |
| 2013 | 6.60% | 3.22% | 1.10x | 1.86x | Rp-3.19 Billion |
| 2014 | 2.74% | 1.20% | 1.29x | 1.78x | Rp-7.05 Billion |
| 2015 | 3.05% | 1.42% | 1.36x | 1.58x | Rp-7.04 Billion |
| 2016 | 4.88% | 2.37% | 1.30x | 1.58x | Rp-5.40 Billion |
| 2017 | 6.55% | 3.20% | 1.40x | 1.47x | Rp-3.76 Billion |
| 2018 | 7.10% | 3.37% | 1.34x | 1.57x | Rp-3.45 Billion |
| 2019 | 7.49% | 3.78% | 1.30x | 1.53x | Rp-3.13 Billion |
| 2020 | 14.02% | 7.97% | 1.21x | 1.45x | Rp6.34 Billion |
| 2021 | 3.28% | 0.87% | 0.78x | 4.82x | Rp-11.23 Billion |
| 2022 | 62.25% | 38.47% | 0.47x | 3.44x | Rp231.03 Billion |
| 2023 | -23.88% | -12.14% | 0.46x | 4.26x | Rp-120.90 Billion |
| 2024 | -31.77% | -17.19% | 0.33x | 5.59x | Rp-434.20 Billion |
Industry Comparison
This section compares Pyridam Farma Tbk's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,379,754,595,932
- Average return on equity (ROE) among peers: 22.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pyridam Farma Tbk (PYFA) | Rp732.89 Billion | 7.76% | 8.44x | $76.03 Million |
| Darya-Varia Laboratoria Tbk (DVLA) | $1.20 Trillion | 16.72% | 0.40x | $8.73 Million |
| Indofarma Tbk (INAF) | $292.57 Billion | 37.70% | 0.84x | $4.64 Million |
| Merck Tbk (MERK) | $416.74 Billion | 25.87% | 0.37x | $11.43 Million |
| Phapros Tbk PT (PEHA) | $821.61 Billion | 12.42% | 1.55x | $4.70 Million |
| Sido Muncul PT (SIDO) | $2.90 Trillion | 22.87% | 0.15x | $192.60 Million |
| Tempo Scan Pacific Tbk (TSPC) | $2.64 Trillion | 18.49% | 0.36x | $70.32 Million |